Skip to main content

Table 1 Summary of the characteristics of the included studies

From: Safety of single-dose primaquine as a Plasmodium falciparum gametocytocide: a systematic review and meta-analysis of individual patient data

PMID Study design Location ACT FU (days) N total % PQ Target dose Age
1  Unpublished MDA Kenya AP 7 291 98 0.144, 0.208 All
27825738 RCT The Gambia DP 42 689 75 0.2, 0.4, 0.75 > 1 year
3  27287612 RCT Tanzania AL 28 220 50 0.25 ≥ 1 year
4  29548285 RCT Sudan ASSP 42 231 52 0.25 ≥ 1 year
5  26952094 RCT Burkina Faso AL 14 360 69 0.25, 0.4 2–15 years
6  18074034 RCT Sudan ASSP 14 100 49 0.75 ≥ 6 months
7  Unpublished RCT Kenya DP 42 54 78 0.125, 0.25, 0.4, 0.75 1 ≤ 12 years
8  24239324 RCT Uganda AL 28 454 75 0.1 0.4 0.75 1–10 years
29324864 RCT and cohort Burkina Faso AL 28 78 87 0.25, 0.4 18–45 years
10  29324864 RCT The Gambia DP 28 61 82 0.25, 0.4 ≥ 10 years
11  28605472 RCT Senegal AL, ASAQ, DP 28 267 50 0.25 > 18 years
12  27450652 Cohort Eswatini AL 7 94 100 0.25 > 1 year
13  17925871 RCT Tanzania ASSP 42 107 50 0.75 3–15 years
14  20194698 MDA Tanzania ASSP 7 840 93 0.75 1–12 years
15  23175563 RCT Indonesia DP 42 373 52 0.75 ≥ 5 years
16  31234865 RCT South Africa AL 42 140 50 0.25 > 1 year
17  28931236 RCT Kenya DP 14 114 51 0.25 5–15 years
18  27128675 Cohort Bangladesh AL 28 115 100 0.75 > 1 year
19  26906747 RCT Mali DP 28 81 80 0.0625, 0.125, 0.25, 0.5 5–50 years
20  27010542 MDA Thailand DP 7 1737 100 0.25 > 6 months
  1. ACT artemisinin-based combination therapy, MDA mass drug administration, AL artemether-lumefantrine, AP artesunate-piperaquine, ASAQ artesunate-amodiaquine, ASSP artesunate sulfadoxine-pyrimethamine, DP dihydroartemisinin-piperaquine, PQ primaquine, RCT randomised controlled trial, FU follow-up time